Clinical and economic effectiveness of allergyspecific immunotherapy in atopic bronchial asthma
In conditions of market relations economic problems of healthcare are central to the activity as health care managers so and practitioners. It is necessary search and implementation of processes for more efficient and effective use of financial resources. Asthma remains one of the most common chronic diseases. Asthma causes significant economic damage. The only significant pathogenetic treatment of atopic diseases is allergen-specific immunotherapy (ASIT). ASIT is the only method of treatment, which allows seek long-term remission of allergic disease, prevent the development of its more severe forms and complications. Taking into account the direct and indirect costs of treating patients with atopic asthma during ASIT it requires less financial expenses comparably with conduct of only pharmacotherapy. Therefore ASIT is reasonable, appropriate and effective treatment and can be recommended for use under conditions of budget cuts of health authorities.